ChromoCure (Genome Research Group) Announces Clinical Testing and Trials for Cervical Cancer Detection Commencing July 15th, 201
13 5월 2010 - 9:30PM
Marketwired
ChromoCure, Inc. (Genome Research Group, Inc,) (PINKSHEETS: KKUR)
today announced its Clinical Testing and Trials for its landmark
ChromoSomal Scanning Technology as applied to cervical cancer.
These Clinical Testing and Trials are anticipated to be the first
in a series relating to the different forms of cancer. The Cervical
Clinical Trials will apply the Company's detection technology to
standard "Pap Smear" slides in order to demonstrate the
effectiveness of detection and the specificity of the scan. The
Clinical Trial Phase 1 is expected to be completed by 15 April
2011, at which time, the Company will apply for regulatory approval
for Europe-wide permission to introduce the company's systems and
technology to participating laboratories.
The clinics and laboratories participating in the trial will be
announced immediately subsequent to the July 15th, 2010 planned
commencement date. Preliminary data of the Phase 1 Trial are
expected to be published on or about 15 December 2010.
The Company's cancer detection technology is based on the
chromosomal theory of cancer. Research has conclusively and
irrefutably demonstrated aneuploidy a more accurate predictor of
cancer than cytological/histological analysis or genetic
marker-based diagnostics that are the only other methods in
existence today. The Company's cancer detection system locates and
measures unique genomic characteristics found in 100% of all
cancers and never found in normal cells. The Company's detection
technology has an effective 100% accuracy rate and an effective
100% specificity therefore making "false positives" and "false
negatives" theoretically impossible.
The Company possesses advanced detection and therapeutic
technology and protocols, comprised of ChromoCure's advanced
detection system and GRG's full line of therapeutic protocols and
technology; allowing for the first time real-time progression
monitoring and remission detection -- providing the world's first
cure research fully integrated system for the precise measurement
of treatment and on-demand, real-time cancer progression analysis
to monitor and determine treatment efficacy.
The Company's recently announced merger with GRG will be of
mutual benefit in advancement of their shared objective; as a
focused Cancer Therapy and Cure Research & Development
organization. The announced merger and acquisition of GRG prepares
the group for a leading role in this new era of cancer research,
detection and therapy.
The combined entity possesses complementary detection and
therapeutic technology and protocols. Management believes the
transaction to be of significant long-term shareholder value and
furthers the Company's transition to research, technology
development, and licensing as a source of significant long-term and
recurring revenues and equity appreciation.
The Company's focus on cancer research is further underscored by
recent major clinical publications that both validate ChromoCure's
chromosomal/aneuploidy theory of cancer and establish the company's
detection approach as the forefront of both cancer detection and
research. The Mayo Clinic's recent landmark findings confirming
aneuploidy as the cause of cancer were published in the December
2009 Cancer Cell journal. This publication has spurred increased
worldwide research by a number of respected research universities
and institutions, all of which have published similar reports in
2010.
This announcement, together with the recently announced the Euro
Zone launch of its Pathologist Collaborative Research (PCR) Program
in support of the groundbreaking Project Boveri: Find the Cure
Initiative, further establish the Company's leading role in the new
era of cancer research, detection, and therapy, as the companies
leverage their combined technologies, research knowledge and
industry relationships.
About Genome Research Group, Inc.
The Company develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary cancer detection system locates and measures unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's detection technology has a proven
and effective accuracy of 100% for all cancers at all stages. The
Company's proprietary Therapeutic Modeling Protocols provide
statistical modeling and prediction tools for the measurement and
monitoring of cancer progression and remission. The Company also
applies its technology and knowledge to cancer cure and
therapeutics research. The Company owns proprietary cancer
detection systems and related therapeutic technologies and
proprietary techniques for non-toxic and non-invasive cancer
therapy utilizing hypothermic modulation and resonance. The
Company's proprietary CS200 Chromosomal Scanner has been proven
accurate and efficient in the measurement of the unique genomic
characteristic found in 100% of all cancers and never found in
normal cells. The Company's detection technology has an effective
accuracy of 100% for all cancers at all stages. GRG's advanced
Therapeutic Modeling and Treatment Protocols combined with its
industry and medical research collaborations validate its
leadership role in Cancer Detection, Therapy and Cure.
The Company believes its technology will become the worldwide
gold standard for cancer detection, progression measurement, and
research for both therapy and cure. The Company also applies its
technology and knowledge to cancer cure and therapeutics
research.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
ChromoCure, Inc. (to be renamed Genome Research Group,
Inc.) www.ChromoCure.com www.GenomeResearchGroup.com
info@genomeresearchgroup.com Tel: +011 (44) 20 7101 9475
Chromocure (CE) (USOTC:KKUR)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Chromocure (CE) (USOTC:KKUR)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024